


1615  
RECEIVED

SEP 25 2003

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT:	Eric H. Kuhrts	<b>CERTIFICATE OF DEPOSIT UNDER 37 C.F.R. § 1.8</b>  I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail, postage prepaid, under 37 C.F.R. § 1.8 on the date indicated below and is addressed to Mail Stop Non-fee Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.   Name <u>Eric H. Kuhrts</u>  <u>9/16/03</u> Date of Deposit
SERIAL NO.:	09/495,556	
FILING DATE:	2/01/2000	
FOR:	SUSTAINED-RELEASE MICROENCAPSULATED DELIVERY SYSTEM	
ART UNIT:	1615	
EXAMINER:	Liliana Di Nola Baron	
DOCKET NO.:	21208	

21208  
SEP 16 2003  
10-1803

THORPE NORTH & WESTERN, LLP  
8180 South 700 East, Suite 200  
Sandy, Utah 84070

AMENDMENT UNDER 37 C.F.R. § 1.115

Mail Stop Non-fee Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

The present amendments and remarks are in response to the Notice of Non-Compliant Amendment mailed on September 5, 2003, which stemmed from Applicant's preliminary amendments filed with the Request for Continued Examination (RCE). Reconsideration of the present application is respectfully requested in view of the following compliant amendments and remarks.

### **INTRODUCTORY COMMENTS FOR AMENDMENTS**

Please amend the claims in the manner indicated below. In the following amendments, an underline is used to indicate new text, and strikeouts are used to indicate deleted text. Claims 1-50, 95, 99-100, and 106 have been cancelled. The amendments to claims 51-52, 58-60, 65, 73-75, 80-81, 87-89, 94, 101, 103, and 105 are supported by the specification and claims of the original application as filed. Specifically, the amendments to independent claims 51, 65, and 80 are supported by Examples 2 and 3 in the specification as originally filed. Also, claim 94 was amended to include a limitation that the pharmaceutical composition is a sustained-release pharmaceutical composition (as stated in the title), and that the animal or vegetable oil is present at from 3% to 20% by weight of the sustained-release pharmaceutical composition. Furthermore, claims 52, 58-60, 73-75, 81, 101, 103, and 105 were amended for clarification purposes. Accordingly, it is believed that no new matter is added by the following amendments to the claims.